OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
May 17, 2023
Webinar Date/Time: Wed, Jun 14, 2023 11:00 AM EDT
May 16, 2023
Under the collaboration, BiOneCure Therapeutics and Nanjing Leads Biolabs intend to develop a range of innovative antibody-drug conjugates for treating solid tumors.
Webinar Date/Time: Wednesday May 31, 2023 at 11am EDT | 10am CDT | 8am PDT
Webinar Date/Time: Tuesday June 13, 2023 at 11 am EDT | 4pm BST | 5pm CEST
May 12, 2023
Dr. Ulrike Lemke, Head of Sterile Fill Finish at Recipharm, sat down with Grant Playter, associate editor, to discuss drug delivery forms.
Webinar Date/Time: Wed, May 24, 2023 2:00 PM EDT
May 04, 2023
Vibha Jawa, executive director at Bristol Myers Squibb, discusses foreign epitopes recognition from what should be fully human antibody therapies.
May 03, 2023
The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.
The use of smart tools in early drug discovery can have an impact on downstream phases of drug development.
The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.